U.S. Patent and Trademark Office issues final rejection of all claims in Rampart IC’s radiation shield patent following reexamination challenge by Egg Medical

ST. PAUL, Minnesota, United States July 2025 – In a significant development in an ongoing legal dispute, the U.S. Patent and Trademark Office (USPTO) has issued a final rejection of all claims in U.S. Patent No. 11,660,056, a patent held by Rampart IC related to a radiation shielding device. 

Egg Medical’s reexamination request arose out of a lawsuit that Rampart filed a lawsuit in federal court in 2024, in which Rampart alleged that Egg Medical had infringed on its ’056 patent. However, after the USPTO twice rejected all claims in the ’056 patent, the federal judge overseeing the case stayed the proceedings pending the outcome of the reexamination. In July 2025, the USPTO’s Central Reexamination Unit issued a final rejection of all claims, citing numerous multiple prior inventions that Rampart failed to disclose—two of which were developed by Egg Medical.

“The remarkable part of this lawsuit is that Egg Medical never sold any product that fell within the scope of Rampart’s now-rejected invalidated patent claims,” said Robert F. Wilson, MD, CEO of Egg. “Egg Medical respects prior intellectual property. The USPTO rejecting the claims in Rampart’s asserted ’056 patent validates what we have been saying all along.”

“The lawsuit was harmful to our company, as Rampart’s sales team at times suggested to customers that we were infringing on their ’056 patent—an assertion that was never true," Gavin Philipps, chief commercial officer at Egg Medical, added. "We’re pleased that the USPTO has thoroughly and repeatedly rejected all of Rampart’s claims in that patent, and we’re glad our customers now have clarity.”

Rampart IC may still respond to appeal the USPTO’s final rejection or appeal to the U.S. Patent Trial and Appeal Board. After three rounds and a sweeping final rejection, however, Rampart’s options are dwindling. However, such appeals are rarely successful, particularly in cases involving a comprehensive rejection based on multiple references.

For further information, please contact:

Susan Storm

Manager, Marketing, Egg Medical, Inc.

E-mail: [email protected]